Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects.
Phase of Trial: Phase III
Latest Information Update: 19 Jun 2018
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Sponsors AbbVie
- 19 Jun 2018 Results presented at the 4th Congress of the European Academy of Neurology
- 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
- 08 Sep 2012 Status changed from active, no longer recruiting to completed according to European Clinical Trials Database record Eudra2006-000578-53.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History